Insider · CIK 0001134655

GADICKE ANSBERT

Reports to the SEC for 46 companies · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001134655

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-01-12	AKTSAktis Oncology, Inc.C Conversion	10% Owner	CConversion	+1.31M sh	—	—	1,655,971
2026-01-12	AKTSAktis Oncology, Inc.C Conversion	10% Owner	CConversion	+5.91M sh	—	—	7,570,168
2026-01-12	AKTSAktis Oncology, Inc. · Series Seed Redeemable Convertible Preferred StockC Conversion	10% Owner	CConversion	−5M sh	—	—	0
2026-01-12	AKTSAktis Oncology, Inc. · Series B Redeemable Convertible Preferred StockC Conversion	10% Owner	CConversion	−6M sh	—	—	0
2026-01-12	AKTSAktis Oncology, Inc. · Series A Redeemable Convertible Preferred StockC Conversion	10% Owner	CConversion	−22.5M sh	—	—	0
2026-01-12	AKTSAktis Oncology, Inc.P Purchase	10% Owner	PPurchase	+1.11M sh	$18.00	+$20M	10,260,064
2026-01-12	AKTSAktis Oncology, Inc.C Conversion	10% Owner	CConversion	+1.58M sh	—	—	9,147,287
2025-12-04	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−83.2K sh	$0.97	−$80.7K	4,784,111
2025-12-03	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−57.2K sh	$0.87	−$49.8K	4,867,341
2025-12-02	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−59.3K sh	$0.89	−$52.8K	4,924,566
2025-12-01	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−60.9K sh	$0.94	−$57.3K	4,983,843
2025-11-28	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−20.3K sh	$0.99	−$20.1K	5,044,760
2025-11-26	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−60.7K sh	$0.98	−$59.5K	5,065,037
2025-11-25	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−42.5K sh	$0.92	−$39.1K	5,125,770
2025-11-24	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−88.8K sh	$0.98	−$87K	5,168,303
2025-11-21	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−64.3K sh	$0.83	−$53.4K	5,257,105
2025-11-20	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−41.2K sh	$0.89	−$36.6K	5,321,436
2025-11-19	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−66.3K sh	$0.94	−$62.3K	5,362,588
2025-11-18	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−52.6K sh	$0.93	−$48.9K	5,428,912
2025-11-17	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−57.1K sh	$0.95	−$54.2K	5,481,539
2025-11-14	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−61.6K sh	$0.93	−$57.3K	5,538,600
2025-11-13	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−91K sh	$0.98	−$89.1K	5,600,240
2025-11-12	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−40.7K sh	$1.09	−$44.3K	5,691,191
2025-11-11	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−55.8K sh	$1.14	−$63.6K	5,731,860
2025-11-10	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−48.6K sh	$1.18	−$57.3K	5,787,670
2025-11-07	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−68.5K sh	$1.11	−$76K	5,836,240
2025-11-06	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−54.5K sh	$1.21	−$65.9K	5,904,720
2025-11-05	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−48K sh	$1.22	−$58.5K	5,959,172
2025-11-04	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−140K sh	$1.22	−$171K	6,007,122
2025-11-03	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−94.1K sh	$1.29	−$121K	6,147,610
2025-10-31	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−114K sh	$1.28	−$146K	6,241,673
2025-10-30	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−86.9K sh	$1.43	−$124K	6,355,717
2025-10-29	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−134K sh	$1.55	−$208K	6,442,653
2025-10-28	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−69.1K sh	$1.64	−$113K	6,576,893
2025-10-27	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−72.7K sh	$1.72	−$125K	6,645,961
2025-05-13	iTeos Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−1.03M sh	$8.06	−$8.32M	3,452,797
2025-03-27	HOWLWerewolf Therapeutics, Inc.S Sale	Former 10% Owner	SSale	−4,386 sh	$1.05	−$4,605.3	6,718,670
2025-03-27	HOWLWerewolf Therapeutics, Inc.X Exercise of In-Money	Former 10% Owner	XExercise of In-Money	+50.9K sh	$0.09	+$4,578.57	6,723,056
2025-03-27	HOWLWerewolf Therapeutics, Inc. · Warrant (Right to Buy)X Exercise of In-Money	Former 10% Owner	XExercise of In-Money	−8,031 sh	—	—	0
2025-03-27	HOWLWerewolf Therapeutics, Inc. · Warrant (Right to Buy)X Exercise of In-Money	Former 10% Owner	XExercise of In-Money	−42.8K sh	—	—	0
2023-06-01	TCR2 THERAPEUTICS INC.J Other	Director, 10% Owner	JOther	−3.37M sh	—	—	0
2023-06-01	TCR2 THERAPEUTICS INC.J Other	Director, 10% Owner	JOther	−3.85M sh	—	—	0
2023-06-01	TCR2 THERAPEUTICS INC.J Other	Director, 10% Owner	JOther	−304K sh	—	—	0
2023-05-22	TCR2 THERAPEUTICS INC.S Sale	Director, 10% Owner	SSale	−70.2K sh	$1.88	−$132K	304,001
2023-05-22	TCR2 THERAPEUTICS INC.Common Stock Warrant (Right To Buy)X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−42.8K sh	—	—	0
2023-05-22	TCR2 THERAPEUTICS INC.Common Stock Warrant (Right to Buy)X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−136K sh	—	—	0
2023-05-22	TCR2 THERAPEUTICS INC.X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	+178K sh	$0.74	+$132K	374,171
2022-07-28	KLRSKalaris Therapeutics, Inc.A Award	Director, 10% Owner	AAward	+3.25M sh	$4.61	+$15M	16,674,766
2022-06-22	CGEMCullinan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+16.5K sh	—	—	16,475
2022-05-17	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, 10% Owner	AAward	+27.5K sh	—	—	27,500

Recent filings

Accepted (ET)
Jan 144
GADICKE ANSBERT0001231919-26-000055
SEC(opens sec.gov)
Dec 44
GADICKE ANSBERT0001231919-25-000574
SEC(opens sec.gov)
Dec 14
GADICKE ANSBERT0001231919-25-000564
SEC(opens sec.gov)
Nov 254
GADICKE ANSBERT0001231919-25-000550
SEC(opens sec.gov)
Nov 204
GADICKE ANSBERT0001231919-25-000533
SEC(opens sec.gov)
Nov 174
GADICKE ANSBERT0001231919-25-000507
SEC(opens sec.gov)

Companies

Address

C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100

BOSTON, MA, 02116